Today's After-Hours Movers

Homology Medicines, Inc. (NASDAQ: FIXX) 20.2% LOWER; announced today promising initial clinical data from the first gene therapy clinical trial in phenylketonuria (PKU). The pheNIX trial is a Phase 1/2 randomized, concurrently controlled, dose-escalation study for adults with PKU. As of December 2, 2019, two patients had received investigational HMI-102 gene therapy in Cohort 1 (low-dose) and one patient in Cohort 2 (mid-dose). Preliminary safety data from Cohorts 1 and 2 showed HMI-102 was well-tolerated. Efficacy data from the first patient in Cohort 2 indicated a dose-response effect with an observed reduction in phenylalanine (Phe) levels from baseline, increase in tyrosine (Tyr), and reduction in the Phe/Tyr ratio, suggestive of increased enzymatic activity. Phe is a registrable endpoint in PKU, Tyr is a product of Phe metabolism and a precursor to neurotransmitters, and the Phe/Tyr ratio is a clinically relevant diagnostic measurement for PKU.

Pacific Biosciences of California (NASDAQ: PACB) 9.4% LOWER; The Federal Trade Commission has authorized an action to block Illumina Inc.s (NASDAQ: ILMN) proposed $1.2 billion acquisition of Pacific Biosciences of California (PacBio) (NASDAQ: PACB). The Commission alleges in an administrative complaint (a public version of which will be available and linked to this news release as soon as possible) that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing (NGS) systems by extinguishing PacBio as a nascent competitive threat.

FedEx (NYSE: FDX) 6.6% LOWER; reported Q2 EPS of $2.51, $0.25 worse than the analyst estimate of $2.76. Revenue for the quarter came in at $17.3 billion versus the consensus estimate of $17.58 billion. FedEx sees FY2020 EPS of $10.25-$11.50, versus the consensus of $12.03.

Steelcase (NYSE: SCS) 5.1% HIGHER; reported Q3 EPS of $0.46, $0.11 better than the analyst estimate of $0.35. Revenue for the quarter came in at $955 million versus the consensus estimate of $934.7 million. Steelcase sees Q4 revenues of $905-$930 million, versus the consensus of $950 million. Steelcase sees FY2020 EPS of $1.41-$1.45, versus the consensus of $1.35. Steelcase sees FY2020 revenues of $3.7 billion, versus the consensus of $3.71 billion.

Neoleukin Therapeutics, Inc. (Nasdaq: NLTX) 4.5% LOWER; announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an underwritten public offering. Neoleukin expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the offering. All of the shares are being offered by Neoleukin. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Cintas Corp. (NASDAQ: CTAS) 2.7% HIGHER; reported Q2 EPS of $2.27, $0.24 better than the analyst estimate of $2.03. Revenue for the quarter came in at $1.84 billion versus the consensus estimate of $1.82 billion. Cintas Corp. sees FY2020 EPS of $8.65-$8.75, versus the consensus of $8.61. Cintas Corp. sees FY2020 revenue of $7.29-7.33 billion, versus the consensus of $7.31 billion.

Noble Corporation plc (NYSE: NE) 2.6% HIGHER; announced that Stephen M. Butz, (48), has been named as Executive Vice President and Chief Financial Officer of the Company, effective December 19, 2019.